Investor Overview

Corporate Profile


Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral virus, which we refer to as LVV, adeno-associated virus, which we refer to as AAV, gene therapy platforms.

Stock Information

NASDAQ | RCKT (Common Stock)

$21.00

 1.27 (6.44%)

High$21.08
Low$19.63
Volume112,417
Market Cap$782,509,439

October 16, 2018  4:00 p.m. ET

Minimum 15 minute delay, Data provided by Nasdaq

Stock chart for: RCKT.O.  Currently trading at $21.00 with a 52 week high of $25.96 and a 52 week low of $7.84.